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Predictive nomogramPurpose: Due to the established role of the human papillomavirus (HPV), the optimal treatment for oro-
pharyngeal carcinoma is currently under debate. We evaluated the most important determinants of
treatment outcome to develop a multifactorial predictive model that could provide individualized predic-
tions of treatment outcome in oropharyngeal carcinoma patients.
Methods: We analyzed the association between clinico-pathological factors and overall and progression-
free survival in 168 OPSCC patients treated with curative radiotherapy or concurrent chemo-radiation. A
multivariate model was validated in an external dataset of 189 patients and compared to the TNM staging
system. This nomogram will be made publicly available at www.predictcancer.org.
Results: Predictors of unfavorable outcomes were negative HPV-status, moderate to severe comorbidity,
T3–T4 classiﬁcation, N2b–N3 stage, male gender, lower hemoglobin levels and smoking history of more
than 30 pack years. Prediction of overall survival using the multi-parameter model yielded a C-index of
0.82 (95% CI, 0.76–0.88). Validation in an independent dataset yielded a C-index of 0.73 (95% CI, 0.66–
0.79. For progression-free survival, the model’s C-index was 0.80 (95% CI, 0.76–0.88), with a validation
C-index of 0.67, (95% CI, 0.59–0.74). Stratiﬁcation of model estimated probabilities showed statistically
different prognosis groups in both datasets (p < 0.001).
Conclusion: This nomogram was superior to TNM classiﬁcation or HPV status alone in an independent
validation dataset for prediction of overall and progression-free survival in OPSCC patients, assigning
patients to distinct prognosis groups. These individualized predictions could be used to stratify patients
for treatment de-escalation trials.
 2014 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 113 (2014) 324–330An increasing body of evidence has shown the relationship
between the human papilloma virus (HPV) and squamous cell car-
cinoma of the oropharynx (OPSCC) [1–3].
Several studies have demonstrated that HPV-associated oro-
pharyngeal cancer has a distinctly better survival after treatment,
compared to HPV-negative tumors. However, the prognosis of
HPV-positive oropharyngeal cancer seems to be signiﬁcantly worse
if there is a history of smoking [4,5]. This accumulated evidence
suggests that tailored OPSCC cancer therapies, in which speciﬁc
information about HPV status and other patient characteristics
are taken into account, need to be designed as a step forward from
current population based therapies.A tool that combines these factors to accurately anticipate
patient’s outcome is needed. An analysis of the RTOG 0129 study
proposed a stratiﬁcation algorithm, combining HPV, T-stage, N-
stage and smoking history, to assign patients into different prog-
nostic groups [2]. This single-cohort based algorithm, although
able to discriminate patients according to their risk of failure,
was based on patients treated within a randomized trial with strict
inclusion criteria, including mainly patients with T3–T4 tumors
and with limited comorbidity.
A recent approach called rapid learning, which aims to drive the
process of knowledge discovery by routinely and iteratively learn-
ing from data generated through patient care, proposes an alterna-
tive for knowledge extraction to evidence based clinical trials [6,7].
Clinical and outcomes information of unselected patients trea-
ted with different treatment modalities and with a larger heteroge-
neity in terms of stages, demographics and comorbidities can be
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patient in daily clinical practice, particularly for the advance
elderly or with high comorbidities, frequently excluded from clin-
ical trials.
This approach has been explored recently, successfully stratify-
ing consecutive patients into distinct risk groups [8]. Unfortu-
nately, an external validation of this model is not yet available.
In this study we evaluated the most important prognostic fac-
tors in OPSCC patients, treated with (chemo) radiation, such as
HPV and smoking history, in combination with other patient and
tumor characteristics to develop a robust nomogram that could
provide individualized predictions of treatment outcome. The pro-
posed predictive nomogram was externally validated in an inde-
pendent cohort of consecutive OPSCC patients. As this knowledge
was extracted from patients in routine clinical care, it can subse-
quently be implemented in clinical practice: it will improve the
information given to patients regarding their prognosis, and could
allow eligibility for treatment de-escalation trials.Materials and methods
Study population
All consecutive patients with OPSCC, stages (I–IVb) treated at
Maastro Clinic between January 2000 and October 2011. 168
patients were included, treated with curative intent (including
deﬁnitive radiotherapy or concurrent chemo-radiation). This anal-
ysis was approved by the Institutional Review Board (No. 11-29-
14/09-intern-6430; NCT01985984).Treatment details
Treatment options were either deﬁnitive radiotherapy alone or
concurrent chemo-radiation with high dose cisplatin every
3 weeks. Patients treated with deﬁnitive radiotherapy received a
continuous course of radiotherapy delivered by 4–6 MV linear
accelerator. Patients were treated with fractionation schedules:
patients with early oropharyngeal cancers (stage I–II) were treated
with Accelerated Fractionated RadioTherapy (AFRT) to 68 Gy in 34
fractions over 37–38 days, the ﬁrst 23 fractions 2 Gy daily, and the
last 11 fractions twice daily in fractions of 2 Gy. Patients in moder-
ate general condition, who were deemed unﬁt for AFRT received
standard fractionated radiotherapy to 70 Gy in 35 fractions over
7 weeks.HPV testing
To determine HPV status formalin-ﬁxed, parafﬁn-embedded
(FFPE) biopsy material of histopathologically conﬁrmed OPSCC
were retrieved from the archives of the Department of Pathology,
University Hospital Maastricht, The Netherlands. FFPE material
had been classiﬁed by histopathology and analyzed by means of
p16INK4A immunostaining and for the presence of oncogenic
HPV16 DNA by PCR in 168 available specimens [9]. A tumor was
considered HPV positive if the HPV16 DNA by PCR results were
positive.Statistical analysis
The factors evaluated for their prognostic potential were HPV
status, smoking and alcohol history, patient comorbidity, pre-
treatment hemoglobin levels, gender, age, tumor location and
TNM classiﬁcation. All patient and treatment characteristics were
collected from medical records. Patient comorbidity was scored
using the Adult Comorbidity Evaluation 27 [10].N-stage was subdivided into two categories comparing N0–N2a
stage against N2b–N3 stage since patients in these categories have
different clinical implications [8,11]. Missing values were imputed
using the predictive mean matching algorithm [12].
Study endpoints were progression-free survival and overall
survival, calculated from the start of radiotherapy. An event for
progression-free survival was deﬁned as death or the ﬁrst docu-
mented recurrence either recurrent local–regional disease or
distant metastases after treatment. For overall survival, data were
considered right-censored if patients were still alive at the time of
last follow-up. For progression-free survival analysis, data were
considered right-censored if patients did not develop a local–regio-
nal recurrence or distant metastases and were alive at the time of
last follow-up.
The X2-test was used for comparisons of categorical variables.
For univariate survival analysis, the Kaplan–Meier method was
used. Groups were compared using the log rank test.
A multivariate Cox Proportional Hazard Regression analysis was
performed to establish factors independently contributing to treat-
ment-outcome. Two-sided p-values of <0.05 were considered sta-
tistically signiﬁcant. A multivariate model combining the most
important predictors was converted into a visual nomogram [13],
and validated in an external cohort of patients from the VU Univer-
sity Medical Center, Amsterdam, The Netherlands. Model perfor-
mance was evaluated using the C-index. The maximum value of
the C-index is 1.0; indicating a perfect prediction model. A value
of 0.5 indicates that 50% of the patients are correctly classiﬁed.
Bootstrapping was used to obtain model prediction conﬁdence
intervals. The Maastro and external validation cohorts were split,
using this model, into three subgroups according to the 33 and
66 percentiles of the risk score. The nomogram will be publicly
available on the website www.predictcancer.org, after publication.
Raw data of the training dataset is available on https://www.can-
cerdata.org/10.1016/j.radonc.2014.09.005. Analyses were per-
formed using SPPS 19.0 (SPSS Inc., Chicago) and Matlab 7.11.0
(The MathWorks Inc., Natick, MA).Validation cohort
Patient characteristics of the validation cohort are shown in
Supplementary Table 1. It consisted of a consecutive series of
189 OPSCC patients curatively treated at the VU University Medical
Center, Amsterdam, The Netherlands, between January 2000 and
December 2006. Treatment options included deﬁnitive radiother-
apy alone and chemo-radiation. The deﬁnitive radiotherapy regime
consisted of standard fractionated radiotherapy to 70 Gy in frac-
tions of 2 Gy over 7 weeks. The concomitant chemo-radiation
scheme included daily fractionation of 2 Gy up to 70 Gy with a con-
comitant intra-venous administration of cisplatin with a dose of
100 mg/m2 at three weeks intervals.Results
Patient, tumor and treatment characteristics are shown in
Table 1. The majority of the patients were male (74.4%) and the
median age at the start of therapy was 59 years (range: 43–
83 years). The median follow-up of all patients was 26 months
(range: 2.5–127.2) and it was 37.5 months (range: 6.4–127.2) for
patients alive at last follow-up. At the time of last follow-up
60.1% of patients were alive and 39.9% had deceased. Progres-
sion-free survival was 47% at 5 years with a total of 76 (45%)
events. A total of 29 (17.3%) local–regional recurrences were
observed.
Immunostaining for p16 was positive in 58 cases (34.5%) and
missing in 1.2% of the cases. After HPV DNA testing, a total of 51
Table 1
Patient and tumor characteristics and univariate analysis results; Maastro cohort (n = 168).
Frequency (%) Log rank test p overall survival Log rank test p PF survival
Age (years) 59.5 (43–83) 0.498 0.282
Gender 0.004 0.006
Male 74.4
Female 25.6
Primary tumor sub-location 0.052 0.140
Tonsillar fossa 36.9
Base of tongue 29.8
Oropharynx overlap 25.6
Soft palate 7.7
Differentiation grade 0.486 0.379
Good 6.5
Moderate 51.8
Poor 27.4
SCC nos 10.7
Undifferentiated 3.6
Smoking pack years 30 (0–100)
Split by median (>30) 0.025 0.026
Split by percentiles 0.078 0.083
Alcohol unit years 134 (0–660)
Split by median (>134) 0.042 0.004
Split by percentiles 0.047 0.005
Comorbidity score (ACE-27) 0.000 0.000
None 33.3
Mild 41.1
Moderate 19.0
Severe 6.5
T-stage 0.001 0.004
T1 14.9
T2 27.4
T3 22.6
T4 35.1
N-stage 0.048 0.065
N0 34.5
N1 17.3
N2 44.1
N3 3.6
Nx 0.6
N0–N2a vs N2b–N3 0.021 0.053
P16 immunostaining
Positive 34.5 0.000 0.000
Negative 64.3
Unknown 1.2
HPV status
Positive 30.4 0.000 0.000
Negative 69.6
Treatment 0.065 0.060
Radiation only 67.9
Chemo-radiation 32.1
RT dose (Gy) 68 (60–70) 0.888 0.865
Missing 2 (1.2)
Pre-RT hemoglobin levels (mmol/L) 8.5 (5.1–11.3) 0.006 0.004
326 Predictive nomogram for oropharyngeal carcinoma patients(30.4%) was considered as HPV positive. Due to its importance in
OPSCC patients, we evaluated the association between HPV status
and other patient and tumor characteristics. Overall survival was
signiﬁcantly better for patients with an HPV-positive OPSCC (CI,
83.66–120.21 months), compared to patients with an HPV-nega-
tive OPSCC (CI, 48.6–68.2 months; p < 0.0001). The 5-year overall
survival rates were 82% in the HPV-positive group and 39% in the
HPV-negative group. For progression-free survival, the surviving
rates were 83% and 35% for the HPV-positive and HPV-negative
groups respectively (p < 0.001).
HPV status was positive in 32.5% and 29.6% of female and male
patients respectively. Patients with HPV-positive status were more
likely to have none to moderate comorbidity (72.5% of HPV posi-
tive cases, p = NS; ACE-27 score 0–1); these patients also showed
a clear tendency toward moderate smoking and alcohol consump-
tion compared to HPV-negative patients (p < 0.001). No signiﬁcant
differences were observed when comparing HPV status and nodal
status, tumor stage and age. There was a higher incidence of
HPV-positive tumors in the tonsils and base of tongue, comparedto the other oropharyngeal sub-locations (p = 0.001). Poorly differ-
entiated tumors had signiﬁcant higher incidence of HPV-positivity
compared to well differentiated tumors (p < 0.006).
Univariate analysis was performed to evaluate the prognostic
signiﬁcance of the tumor and patient characteristics shown in
Table 1. The variables that were associated with shorter overall
survival were male gender (p = 0.004), pack years of smoking
higher than the median value (median = 30 pack years;
p = 0.025), unit years of alcohol consumption higher than the med-
ian value (median = 134 unit years; p = 0.042), higher ACE-27
comorbidity index (p < 0.0001), higher T-stage (p < 0.0001), N2b–
N3 stage (p = 0.021), negative HPV status (p < 0.0001) and lower
pre-radiotherapy hemoglobin levels than the median value (med-
ian = 8.5 mmol/L; p < 0.006). Differentiation grade did not show
signiﬁcant differences in overall survival (p = 0.654). Tumors
located in the posterior oropharynx wall had a trend toward worse
survival, compared to other tumor sub-locations (p = 0.052).
Treatment parameters such as radiotherapy delivered dose and
overall treatment time did not show a correlation with overall
E. Rios Velazquez et al. / Radiotherapy and Oncology 113 (2014) 324–330 327survival (p > 0.05). Likewise, no signiﬁcant differences in overall
survival were observed based on treatment type (radiation only
vs. chemoradiation, p = 0.29).
Gender, pack years of smoking, unit years of alcohol consump-
tion, comorbidity, T-stage, HPV status and pre-radiotherapy hemo-
globin levels were individually associated with progression-free
survival (Table 1).
Some prognostic factors in the univariate analysis (Table 1)
were no longer signiﬁcant in the multivariate cox-regression anal-
ysis. For overall survival, the factors that remained as independent
contributors of unfavorable treatment outcome were male gender,
low pre-treatment hemoglobin levels (<median), higher T-stage,
N2b–N3 stage, negative HPV status and high comorbidity (moder-
ate to severe). Multivariate hazard ratios, conﬁdence intervals and
signiﬁcance levels are shown in Table 2.
For progression-free survival male gender, high comorbidity,
higher T-stage, N2b–N3 stage and negative HPV status remained
as signiﬁcant independent prognostic factors. All other parameters
did not show a signiﬁcant correlation with progression-free sur-
vival (Table 2).
Prediction of overall survival yielded a C-index of 0.82 (95% CI,
0.76–0.88) based on the Maastro Clinic dataset. In the independent
external validation dataset, the C-index was 0.73 (95% CI, 0.66–
0.79). The resulting nomogram, shown in Fig. 1, estimates outcome
probabilities by assigning a score to each predictor value. The sum
of these scores corresponds to an outcome event probability. The
most important factor in the nomogram to estimate overall survival
is HPV status. Kaplan–Meier curves of the model estimates for the
development and validation cohorts are shown in Fig. 2a. This strat-
iﬁcation showed signiﬁcant differences in outcomes for the three
proposed risk groups, in both datasets (p < 0.001). For progres-
sion-free survival, the model’s C-index was 0.80 (95% CI, 0.76–
0.88), with a validation C-index in the external dataset of 0.67
(95% CI, 0.59–0.74). Again, the predictive nomogram was able to
estimate individual progression-free survival rates and assign
patients to clearly distinct risk groups in the validation cohort
(p < 0.001; Fig. 2b). A comparison of the multivariate model perfor-
mance with TNM staging, HPV alone and Ang’s model [2] is shown
in Table 3. Median survival rates for the distinct risk groups are
summarized in Supplementary Table 2.Table 2
Multivariate Cox proportional hazards analysis of potential prognostic factors for overall s
Overall survival
Hazard ratio Conﬁdence intervals
Age (years) 1.003 973–1.034
Gender
Female
Male 2.511 1.199–5.258
Pre-RT hemoglobin levels .693 .531–.903
Pack years of smoking 1.006 .992–1.021
Unit years of alcohol consumption 1.001 .999–1.002
T-Stage
T1
T2 .945 .337–2.759
T3 3.284 1.287–8.437
T4 2.281 .875–5.942
N-Stage
N0–N2a
N2b–N3 2.588 1.413–4.738
Comorbidity
Score (0–1)
Score (2–3) 2.347 1.307–4.216
HPV status
Positive
Negative 6.027 2.487–14.607Discussion
We evaluated the prognostic signiﬁcance of HPV and other fac-
tors of clinical interest, in a large cohort of consecutive OPSCC
patients, to develop a multifactorial predictive model that can pro-
vide individual estimations of treatment outcome in this patient
population.
Combining the most important prognostic factors in a multivar-
iate model, including HPV status, comorbidity score, T-stage, N-
stage, pack years of smoking, gender and pre-treatment hemoglo-
bin levels yielded high predictive performances, as shown by the C-
index for overall survival of 0.82 (95% CI, 0.76–0.88) and of 0.80
(95% CI, 0.76–0.88) for progression-free survival. This model was
validated in an external unselected cohort of OPSCC patients
(n = 189), showing reliable validation model performances for
overall survival (0.73; 95% CI, 0.66–0.79) and progression-free sur-
vival (0.67; 95% CI, 0.59–0.74). Model predictions were signiﬁ-
cantly better than using TNM or HPV alone. Also, this
multivariate model showed higher C-indexes when compared with
the published model based on the RTOG 0129 study including HPV,
T-classiﬁcation, N-classiﬁcation and smoking history [2].
This prognostic model for OPSCC patients has been validated in
an independent dataset by directly applying the model weights to
the validation raw data. Previously published models have been
evaluated in a single development cohort [2,8], although Ang’s
model has been recently evaluated by two groups [8,14]. Our
model was able to stratify patients according to their estimated
risk of failure into distinct risk groups, in both cohorts, for overall
and progression-free survival. However, the performance was
lower for prediction progression-free survival in the validation
cohort.
We followed the so-called rapid-learning approach in which
knowledge is derived from unselected patient databases, as com-
pared to medical evidence derived from clinical trials [6,7]. This
approach has an obvious advantage of including a more heteroge-
neous group of patients, in terms of clinical stage, comorbidity and
treatments. In this way, the knowledge derived can be used for
decisions concerning new patients, including the elderly patient
or the patient with severe comorbidity, which would not be
included in a clinical trial. The clinical and patient characteristicsurvival and progression-free survival.
Progression-free survival
p-Value Hazard ratio Conﬁdence intervals p-Value
.856 1.015 .986–1.044 .320
.015 2.101 1.094–4.037 .026
.007 .802 .633–1.016 0.067
.792 1.006 .993–1.020 .368
.554 1.002 1.000–1.003 .057
.945 1.157 .457–2.931 .759
.014 2.941 1.225–7.063 .016
.092 2.216 .914–5.374 .078
.002 2.332 1.362–3.995 .002
.004 1.728 1.004–2.972 .048
.001 4.746 2.183–10.322 .001
Fig. 1. Multivariate model converted to a graphic nomogram for prediction of overall survival. Each variable in the model, corresponding to the characteristics of an
individual patient, is assigned to an individual score. A probability for overall survival can be calculated by drawing a vertical line from each predictor value to the score scale
at the top—‘points’. After manually summing up the scores, the ‘total points’ correspond to the probability of overall survival (or progression free survival respectively), which
are estimated by drawing a vertical line from this value to the bottom scales to estimate overall survival. Smoking was categorized as none, moderate (1–30 pack years of
smoking) and heavy (>30 pack years of smoking).
328 Predictive nomogram for oropharyngeal carcinoma patientsincluded in this study were selected based on medical expertise,
known prognostic importance from literature and availability
[1,2,15].
In our study, overall survival rates and progression-free survival
rates were comparable with other studies [8,16]. The frequency of
HPV-associated OPSCC in our cohort is comparable to other recent
European series [8,9,16]. Similarly, we found HPV-positive status
to be associated with low smoking and alcohol consumption, and
less likely to have severe comorbidity (p < 0.0001). Furthermore,
the presence of HPV correlated positively with poor differentiation
grade (p < 0.006) and was more often present in tumors of the ton-
sils and the base of the tongue (p = 0.001). These ﬁndings are in line
with previously observed correlations between HPV incidence and
patient demographics and tumor characteristics [9,15,17]. HPV-
positive cancers have been associated with smaller primary tumors
and with greater regional disease [1], in our study, no signiﬁcant
differences in HPV-prevalence were observed among different T-
stages or N-stages.
Tobacco smoking has been established as a major independent-
prognostic factor for patients with OPSCC [4,9,17], these studies
showed that cancer progression and risk of death increases with
tobacco exposure, independently of tumor HPV status and treat-
ment. In our study, pack years of smoking was a signiﬁcant prog-
nostic factor for overall and progression-free survival, however,
in the multivariate analysis, it did not remain as independent prog-
nostic factor.
A limitation in our study, inherent to its retrospective nature is
the lack of standardization in which data have been collected over
the years. Furthermore, smoking behavior during therapy, which
has been recently reported as important prognostic factor
[4,5,18], was not available in our study.
This further highlights the increasing need for systematic
routine patient care data collection, warehouse and semantic
inter-operable data retrieval systems, to assure improved and stan-
dardized data retrieval and allow external applicability [7,19,20].Moderate to severe comorbidity, higher T-stage and advanced
N-stage were independent unfavorable prognostic factors for over-
all survival and progression-free survival. We used the ACE-27
comorbidity score, a validated comorbidity scoring system, which
has been previously associated with patient prognosis in head
and neck cancers [8,21,22]. Advanced clinical T-classiﬁcation has
been reported as a signiﬁcant risk factor for progressive disease
and death in oropharyngeal carcinoma patients [17]. Indeed, T3–
T4 tumors showed poorer survival, compared to T1–T2 tumors.
Similarly, we observed that higher N-stage was associated with
worse survival; however this association was less signiﬁcant with
progression-free survival. Comparing N0–N2a nodal stages against
N2b–N3 stages showed marked differences in survival, with the
latter being an unfavorable prognostic factor. This re-grouping of
N-stage has shown prognostic value previously [8,11]. Male gender
was a strong negative prognostic factor for overall survival and
progression-free survival; however this effect remained signiﬁcant
in the multivariate setting only for overall survival. Other studies
have shown male gender to be an unfavorable prognostic factor,
as well as in other head and neck cancer sites, however in OPSCC
this association can be confounded by the fact that men have a
higher incidence of HPV-positive OPSCC than women [4,17,18,23].
We showed that combining tumor HPV status with other
important prognostic factors, increased the accuracy in the predic-
tions, compared to the traditional TNM staging system or individ-
ually. 95% CI of the model predictions were signiﬁcantly better
than those obtained with TNM alone or HPV status alone, which
underlines the importance of multifactorial prediction models.
This model performance is acceptable for clinical support, par-
ticularly due to the clear distinction in risk groups, in both cohorts;
however it is still far from optimal. Combining clinical parameters
with HPV, is a ﬁrst step into developing validated decision support
systems in head and neck cancer; however we anticipate that add-
ing other features, such as diagnostic and molecular imaging, and
other important biomarkers such as EGFR or CA-IX will increase
Fig. 2. Kaplan–Meier curves of risk group stratiﬁcation for (A) overall survival and (B) progression-free survival. Nomogram risk group stratiﬁcations for the 33 and 66
percentiles are shown for the development cohort (left), and for the validation cohort (right). All survival curves are statistically different (log rank test, p < 0.0001).
Table 3
Multivariate model performance (C-index) and comparison with TNM and HPV.
Models Maastro cohort VUMC cohort
OS PFS OS PFS
Multivariate model 0.82 (CI, 0.76–0.88) 0.80 (CI, 0.75–0.87) 0.73 (CI, 0.66–0.80) 0.67 (CI, 0.60–0.74)
TNM 0.66* (CI, 0.61–0.75) 0.65* (CI, 0.60–0.72) 0.64* (CI, 0.59–0.73) 0.60* (CI, 0.53–0.68)
HPV 0.68* (CI, 0.61–0.72) 0.68* (CI, 0.60–0.74) 0.68* (CI, 0.63–0.73) 0.54* (CI, 0.49–0.59)
Ang’s Model [2] 0.76* (CI, 0.65–0.80) 0.74* (CI, 0.70–0.82) 0.72 (CI, 0.64–0.78) 0.64* (CI, 0.59–0.72)
C-index conﬁdence intervals were obtained in a bootstrap procedure (n = 100).
* Indicates whether the multivariate model performance is signiﬁcantly higher than TNM, HPV or Ang’s model (p = 0.001).
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tion of routine patient care data will likewise increase model reli-
ability and allow further validation.
In conclusion, we showed that combining HPV status with a
set of important clinical parameters allows the development of
multifactorial models to predict overall and progression-free sur-
vival. Applying this model to individual patients can support their
stratiﬁcation according to their estimated risk and their eligibility
for different treatment approaches [11,27], for instance, ongoing
trials are evaluating treatment de-intensiﬁcation for OPSCC with
estimated good prognosis (NCT01663259). Thus, population-
based learning can improve the information given to patients
regarding their prognosis as well as in the long term allow strat-
iﬁcation in prospective clinical trials and treatment
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